Overview:
High-dose methotrexate (HDMTX) is a fundamental treatment for certain cancers but is often complicated by acute kidney injury and delayed drug clearance, resulting in increased toxicity and poorer outcomes. Clinicians frequently encounter difficulties in identifying at-risk patients, understanding methotrexate pharmacokinetics, and implementing evidence-based interventions like leucovorin and glucarpidase to prevent and manage associated oncologic emergencies.
This live virtual webcast will feature a panel of three expert faculty discussing the recognition, prevention, and management of these oncologic emergencies. The initiative includes guideline-focused discussions and integrates clinical decision tools, such as MTXPK, to support improved detection and management of HDMTX toxicities. Participants will be instructed on applying guideline-based recommendations for managing oncologic emergencies in patients with delayed methotrexate clearance after HDMTX administration.
Learning Objectives:
Upon completion of this activity, learners will be better able to:
- Determine supportive care requirements for patients with cancer receiving treatment with high-dose methotrexate (HDMTX)
- Integrate online clinical support tools such as MTXPK to aid identification of delayed methotrexate clearance
- Apply guideline-based recommendations to manage oncologic emergencies in patients with delayed methotrexate clearance following HDMTX administration
Shazia Nakhoda, MD
Assistant Professor, Malignant Hematology
Fox Chase Cancer Center
Philadelphia, PA
Shruti Gupta, MD, MPH
Assistant Professor of Medicine
Harvard Medical School
Director of Onconephrology
Brigham and Women’s Hospital and Dana-Farber Cancer
Institute
Boston, MA
Anitha Varghese, MSN, APRN, AGPCNP-C
Advanced Practice Provider
MD Anderson Cancer Center
Houston, TX
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.
Physicians' Education Resource®, LLC (PER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Physicians' Education Resource®, LLC has approved this application-based activity for 1.00 ACPE CE hours UAN # 0661-0000-25-028-L05-P. Eligibility for credits requires full attendance, engagement in the live activity, completion and submission of the learner NABP ID # and month and day of birth, activity pre- and post-session questions, and the post activity evaluation. This UAN # expires March 31, 2027.